Select Country Canada India Latin America New Zealand Saudi Arabia United States Search Home About Us Press Center For Media Inquiries, Please Contact: Jordan Berman Vice President, Global Corporate Communications Apotex Inc. 150 Signet Drive, North York, ON, M9L 1T9 Canada 416-401-7487 Email Press Center February 2, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings May 26, 2020 APOTEX CORP. DONATES CRITICAL MEDICINES IN THE FIGHT AGAINST COVID-19 May 26, 2020 Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec May 25, 2020 Toronto Company Launches Hiring Blitz During COVID-19 April 21, 2020 Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada April 17, 2020 Canada’s Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers April 13, 2020 Canada’s Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19 March 23, 2020 APOTEX DONATES HYDROXYCHLOROQUINE FOR A CLINICAL STUDY TO PREVENT INFECTION FROM COVID-19 WITH FRONT LINE HEALTH CARE WORKERS March 5, 2020 Apotex Statement: Drug Supply and COVID-19 September 20, 2018 ACCC announces clearance of the merger of Arrow Pharmaceuticals & Apotex Australia & NZ merger Melbourne, September 20, 2018 – The Australian Competition and Consumer Commission (ACCC) announced this morning that it ‘has decided not to oppose the merger of generic pharmaceutical companies, Arrow and Apotex’ after finding the transaction would not substantially lessen competition in any market. July 14, 2018 Apotex Focuses on High Growth Markets with Sale of European Generics Business Sale Part of Previously Announced Plan to Assess Global Footprint June 1, 2018 Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market May 9, 2018 Apotex Announces Proposed Merger of AUS & NZ Operations Apotex Australia, an affiliate of Apotex Inc., headquartered in Toronto, Canada, today announced a proposed merger of their Australian and New Zealand generic pharmaceutical and over-the-counter (OTC) operations with Arrow Pharmaceuticals. June 12, 2017 Apobiologix Applauds Supreme Court Decision in Sandoz Biosimilar Case Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced their support of the Supreme Court decision in the Sandoz v Amgen case. The case clarifies the timing of the Biologics Price Competition and Innovation Act (BPCIA) requiring biosimilar companies to provide 180-days notice to the companies of the reference products of intent to market the biosimilar. June 8, 2017 Canadian Scientists Honored for Role in Breakthrough Drug Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world are being honored at the annual Cooley's Anemia Foundation Gala tonight in New York City. April 28, 2017 University of Saskatchewan, Apotex renew partnership with $1.6M donation to the College of Pharmacy and Nutrition The University of Saskatchewan and Apotex Inc. have renewed their partnership with a $1.6 million donation by the company to the College of Pharmacy and Nutrition. March 8, 2017 Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company's Largest Investment in the United States Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan March 31, 2016 Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada. March 24, 2016 Apotex Launches First Generic Version of Merck's Nasonex® Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States. Legal & Copyright Terms Privacy Policy Global Business Ethics & Compliance UK Tax Strategy Public Advisories FOLLOW US : ABOUT US About Apotex Our Leadership Corporate Responsibility Press Center APOblog PRODUCTS HEALTHCARE PROFESSIONALS R & D BUSINESS OPPORTUNITIES International Business Development Opportunities Co-Development Out-Licensing In EMEA Submit Your Opportunity CAREERS CONTACT US Apotex Worldwide All other brand or product names located in this site are Trademarks of their respective holders. © Apotex Inc. 2021. All rights reserved.